Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
16 shown of 2,542 total abstracts
  1. Abstract 101162026-09-02 · 19:45 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-557
    F. Andre, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  2. Abstract 100022026-09-02 · 16:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-718
    C. Saura, H. Rugo, T. Mok, et al. · University of Chicago
    Oral Abstract SessionMelanoma📄🖼️🎬
  3. Abstract 102012026-09-02 · 14:00 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    M. Krop, M. Reck, P. Schmid, et al. · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  4. Abstract 101502026-09-01 · 14:45 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Peters, J. Cortes, T. Mok · Institut Gustave Roussy
    Oral Abstract SessionMelanoma📄🖼️🎬
  5. Abstract 95082026-09-02 · 19:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-713
    S. Antonia, H. Borghaei · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  6. Abstract 101102026-09-05 · 13:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    F. Andre, J. Cortes, S. Tolaney, et al. · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  7. Abstract 100342026-09-04 · 13:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-177
    G. Curigliano, E. Winer, C. Saura · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  8. Abstract 95462026-09-04 · 21:30 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-860
    M.C. Garassino, G. Curigliano, M. Reck · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  9. Abstract 104502026-09-01 · 13:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-397
    C. Robert, J. Brahmer, M.C. Garassino, et al. · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  10. Abstract 97662026-09-04 · 15:30 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-294
    L. Paz-Ares, E. Winer, P. Schmid · University of Chicago
    Oral Abstract SessionMelanoma📄🖼️🎬
  11. Abstract 99342026-09-03 · 15:15 CT · E450
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-269
    M.C. Garassino, S. Antonia · Peter MacCallum Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  12. Abstract 102022026-09-01 · 20:30 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-429 study)
    S. Antonia, H. Rugo, T. Mok, et al. · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  13. Abstract 104042026-09-01 · 21:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-193
    S. Modi, M. Reck · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  14. Abstract 102092026-09-04 · 15:45 CT · S100A
    CheckMate-1: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    G. Curigliano, S. Tolaney · Karolinska Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  15. Abstract 97902026-09-03 · 15:30 CT · S100A
    KEYNOTE-527: Keytruda (pembrolizumab) 1L in metastatic melanoma
    S. Antonia, M. Reck, C. Saura, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  16. Abstract 97542026-09-03 · 18:45 CT · S406
    CheckMate-780: Opdivo (nivolumab) adjuvant in metastatic melanoma
    S. Antonia, M. Reck, H. Borghaei, et al. · University of Chicago
    Oral Abstract SessionMelanoma📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.